India Daily Briefing

The IPO market is running hot with 15 issues opening or listing this week, including Molbio Diagnostics which raised ₹281 crore in anchor allocation from World Bank's IFC and HDFC AMC—a signal of institutional-grade confidence. With GMP suggesting returns of up to 37% on select issues, SIP investors face the classic lumpsum timing dilemma: subscribe or wait for post-listing dips? Upcoming names include Shiprocket and Dhoot Transmission. Quality-bias anchor rosters reduce subscription risk on the mainboard side, but SME listings deserve extra scrutiny on lock-in periods.

Analysts flagged crude oil prices, West Asian geopolitical tensions (Hormuz remains in focus after Iran-UAE tanker incident), and upcoming US inflation data as the primary market-direction variables for Indian equities this week. For Anjali's read: if US CPI surprises cool, FII outflow pressure could ease meaningfully — India's FII flows have been negative in several recent sessions and a dollar-softening narrative is the cleanest catalyst for reversal. Crude near $80 Brent is tolerable for India's fiscal math; a spike past $90 on Hormuz escalation is the bear case that re-prices the inflation and CAD outlook simultaneously.

Trendlyne consensus estimates highlight nine Nifty 500 stocks with analyst-implied upside of up to 50%, released as the broader mid and small-cap space enters a two-year range-bound phase. PPFAS's Rajeev Thakkar noted that the sideways equity market of the past two years is historically normal and that select opportunities are increasing—a contrarian green light for patient SIP accumulation. The mid and small-cap divergence from Nifty 50 on Friday (+0.22% vs -0.27%) suggests selective stock-picking is rewarding risk this week more than index-following.